Enlicitide chloride | CAS#2407527-16-4 | PCSK9 inhibitor

MedKoo Cat#: 123379 | Name: Enlicitide chloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Enlicitide chloride also known as MK0616, is an orally bioavailable PCSK9 Inhibitor. MK-0616 demonstrates significant LDL-C reduction. MK-0616 displayed high affinity (Ki = 5pM) for PCSK9 in vitro and sufficient safety and oral bioavailability preclinically to enable advancement into the clinic.

Chemical Structure

Enlicitide chloride

CAS#2407527-16-4 (chloride)

Theoretical Analysis

MedKoo Cat#: 123379

Name: Enlicitide chloride

CAS#: 2407527-16-4 (chloride)

Chemical Formula: C82H110ClFN14O15

Exact Mass: 0.0000

Molecular Weight: 1586.31

Elemental Analysis: C, 62.09; H, 6.99; Cl, 2.23; F, 1.20; N, 12.36; O, 15.13

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

2407527-16-4 (chloride) 2407527-14-2 (cation)

Synonym

MK-0616; MK0616; MK 0616; Enlicitide chloride.

IUPAC/Chemical Name

L-Proline, L-alanyl-3-[[1-oxo-6-(trimethylammonio)hexyl]amino]-D-alanyl-3-[[(2-hydroxyacetyl)amino]methyl]-L-phenylalanyl-1-[6-[[[4-(2-aminoethyl)phenyl]methyl](3-carboxy-1-oxopropyl)amino]hexyl]-5-fluoro-L-tryptophyl-(3S)-3-hydroxy-L-prolyl-L-threonyl-O-methyl-L-tyrosyl-2-methyl-, (4→1),(8→4)-dilactam, cyclic (3→5)-ether, chloride (1:1)

InChi Key

KZFXQSLIAQMQRP-MQCRZNPVSA-O

InChi Code

InChI=1S/C81H104FN15O15S2/c1-50-73(101)87-63-40-54-15-10-14-52(35-54)13-8-9-31-112-68-22-27-94-72(68)77(105)90-71(51(2)98)76(104)89-64(39-53-16-19-61(109-7)20-17-53)79(107)95-26-11-24-81(95,3)80(108)83-25-34-114-49-56-36-55(48-113-33-23-69(99)86-66(75(103)85-50)43-84-70(100)47-111-30-12-29-110-32-28-97(4,5)6)37-60(38-56)96-46-59(91-92-96)45-93-44-57(41-65(78(94)106)88-74(63)102)62-42-58(82)18-21-67(62)93/h8-10,14-21,35-38,42,44,46,50-51,63-66,68,71-72,98H,11-13,22-34,39-41,43,45,47-49H2,1-7H3,(H7-,83,84,85,86,87,88,89,90,99,100,101,102,103,104,105,108)/p+1/b9-8+/t50-,51-,63+,64+,65+,66+,68+,71+,72+,81+/m1/s1

SMILES Code

FC=1C=C2C3=CN(C2=CC1)CCCCCCN4CC=5C=CC(=CC5)CCNC(=O)[C@@]6(C)N(C(=O)[C@H](CC7=CC=C(OC)C=C7)NC(=O)[C@]([C@@H](C)O)(NC(=O)[C@]8(N9C(=O)[C@](C3)(NC(=O)[C@](CC=%10C=C(C=CC%10)CNC(=O)CO[C@]8(CC9)[H])(NC(=O)[C@@H](CNC(CCCCC[N+](C)(C)C)=O)NC(=O)[C@H](C)NC(=O)CCC4=O)[H])[H])[H])[H])CCC6.[Cl-]

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite nearly 2 decades of effort, an oral inhibitor of PCSK9 is not available. Macrocyclic peptides represent a novel approach to target proteins traditionally considered intractable to small-molecule drug design.

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,586.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Johns DG, Campeau LC, Banka P, Bautmans A, Bueters T, Bianchi E, Branca D, Bulger PG, Crevecoeur I, Ding FX, Garbaccio RM, Guetschow ED, Guo Y, Ha SN, Johnston JM, Josien H, Kauh EA, Koeplinger KA, Kuethe JT, Lai E, Lanning CL, Lee AYH, Li L, Nair AG, O'Neill EA, Stoch SA, Thaisrivongs DA, Tucker TJ, Vachal P, van Dyck K, Vanhoutte FP, Volckaert B, Wolford DG, Xu A, Zhao T, Zhou D, Zhou S, Zhu X, Zokian HJ, Walji AM, Wood HB. Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor. Circulation. 2023 Jul 11;148(2):144-158. doi: 10.1161/CIRCULATIONAHA.122.063372. Epub 2023 May 1. PMID: 37125593; PMCID: PMC10325562. 2: Gupta K, Balachandran I, Foy J, Hermel M, Latif A, Krittanawong C, Slipczuk L, Baloch F, Samad Z, Virani SS. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American College of Cardiology Conference. Curr Atheroscler Rep. 2023 Jun;25(6):309-321. doi: 10.1007/s11883-023-01103-4. Epub 2023 Apr 22. PMID: 37086374. 3: Ballantyne CM, Banka P, Mendez G, Garcia R, Rosenstock J, Rodgers A, Mendizabal G, Mitchel Y, Catapano AL. Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. J Am Coll Cardiol. 2023 Apr 25;81(16):1553-1564. doi: 10.1016/j.jacc.2023.02.018. Epub 2023 Mar 6. PMID: 36889610.